Strata Skin Sciences, Inc. (NASDAQ:SSKN) Sees Large Growth in Short Interest

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 1,520,000 shares, an increase of 482.2% from the September 30th total of 261,100 shares. Based on an average daily volume of 4,460,000 shares, the short-interest ratio is currently 0.3 days. Currently, 42.7% of the shares of the company are short sold. Currently, 42.7% of the shares of the company are short sold. Based on an average daily volume of 4,460,000 shares, the short-interest ratio is currently 0.3 days.

Strata Skin Sciences Stock Performance

SSKN opened at $1.68 on Tuesday. The firm has a market cap of $8.85 million, a P/E ratio of -0.59 and a beta of 0.50. Strata Skin Sciences has a 52-week low of $1.38 and a 52-week high of $3.86. The company has a debt-to-equity ratio of 49.58, a quick ratio of 0.75 and a current ratio of 0.98. The business’s fifty day moving average is $1.87 and its 200-day moving average is $2.18.

Strata Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings results on Wednesday, August 13th. The medical device company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Strata Skin Sciences had a negative return on equity of 266.94% and a negative net margin of 35.13%.The business had revenue of $7.70 million for the quarter, compared to analyst estimates of $8.56 million. Sell-side analysts expect that Strata Skin Sciences will post -1.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SSKN. Wall Street Zen raised Strata Skin Sciences to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Strata Skin Sciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Strata Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.